By
Drug Target Review2025-08-12T13:30:40
Drug discovery company, TauGen, has filed a US patent application for a new series of drug candidates targeting endoplasmic reticulum (ER) stress – a key factor in secondary brain injury following traumatic brain injury (TBI).
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2026-11-17T09:31:00Z
2023-02-03T13:56:13
Sponsored by Leica Microsystems
2026-09-03T07:00:00
Contributor Marty Parrish and Steve Hoffmann, By Drug Target Review
2026-10-30T07:30:00
Sponsored by Aptamer Group
2023-05-03T15:39:23
Sponsored by BPS Bioscience
2026-11-02T07:00:00
Sponsored by Biointron
2025-09-18T12:00:00
Sponsored by Benchling
Site powered by Webvision Cloud